In the ALS mouse model transgenic for G93A-superoxide dismutase 1 (SOD1-G93A), long-term IL-33 administration delays disease onset in females but not males, probably through peripheral Th2 response (159). Here, IL33 is linked to amyotrophic lateral sclerosis.